(The Consortium of Investigators of Modifiers of BRCA1/2)
Eligibility:
Any group that can contribute DNA and basic phenotype and epidemiological risk factor data from at least 92 female BRCA1 and BRCA2 mutation carriers with a pathogenic mutation
can participate in CIMBA. Carriers must be aged 18 or over and both affected and unaffected individuals are eligible.
